A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hematopoietic and Lymphoid System Neoplasm Clinical Trial

Official title:

A Phase 1b Safety and Immunogenicity Study of Cytomegalovirus (CMV) Directed Type 1 Polarized Dendritic Cell Vaccination (αDC1) After Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Hematologic Malignancies

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05589844
• Other study ID #: I 1289721
• Secondary ID: NCI-2022-05780I
• Status: Withdrawn
• Phase: Phase 1
• Start date: March 2023
• Est. completion date: November 16, 2025

Study information

• Verified date: April 2023
• Source: Roswell Park Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase Ib trial evaluates the safety and most effective dose of a cytomegalovirus (CMV) pp65 peptide-loaded alpha-type-1 polarized dendritic cell (CMV-alphaDC1) vaccination in patients who are undergoing an allogeneic hematopoietic stem cell transplant. CMV is an opportunistic infection that can occur or reactivate after allogeneic hematopoietic stem cell transplant as a result of immunosuppression. The CMV-alphaDC1 vaccine is made of white blood cells that have been exposed to molecules called cytokines, as well as CMV proteins. Introducing these dendritic cells to the patients immune system may activate an immune response to CMV, protecting against infection or reactivation.

Description:

PRIMARY OBJECTIVES: I. Determine the safety of cytomegalovirus (CMV) pp65 peptide loaded alpha-type 1 polarized dendritic cell (CMV-alphaDC1) vaccination after allogeneic hematopoietic cell transplantation (alloHCT). II. Determine the immunogenicity of CMV-alphaDC1 vaccination after alloHCT. SECONDARY OBJECTIVES: I. Evaluate the effect of CMV-alphaDC1 vaccination after alloHCT on late CMV reactivation. II. Evaluate the effect of CMV-alphaDC1 vaccination after alloHCT on non-relapse mortality (NRM). EXPLORATORY OBJECTIVES: I. Assess the effect of CMV-alphaDC1 vaccination on T cell subsets. II. Assess the effect of CMV-alphaDC1 vaccination on T cell receptor diversity. OUTLINE: On day 0, patients undergo standard of care hematopoietic stem cell infusion. Patients receive CMV-alphaDC1 vaccine intradermally on days 28, 42, 56, and 70. After completion of study treatment, patients are followed up at days 84, 100, 180, and 365.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 16, 2025
• Est. primary completion date: November 16, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Recipient age >= 18 years of age
• The recipient is CMV seropositive
• The recipient is planned to receive an allogeneic peripheral blood stem cell graft
• The recipient is planned to receive fludarabine, melphalan, and total body irradiation for the transplant conditioning regimen
• The recipient is planned to receive micro-dose methotrexate, tacrolimus, and mycophenolate mofetil for acute graft versus host disease (GvHD) prophylaxis
• The recipient has an expected hematopoietic cell transplantation-comorbidity index (HCT-CI) score of 4 or less based upon the data available at the time of eligibility assessment
• The recipient must understand the investigational nature of this study and has signed an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedures
• The donor is CMV seronegative or seropositive
• The donor is 8/8 human leukocyte antigen (HLA) (DR-B1, A, B, C) matched to the recipient
• The donor is willing and able to donate peripheral blood mononuclear cells in addition to peripheral blood stem cells
• The donor is willing to sign informed consent

Exclusion Criteria:

• The recipient is CMV seronegative
• The recipient is planned to receive T cell depletion in vivo (anti-thymocyte globulin [ATG], alemtuzumab, post-transplant cyclophosphamide) or ex vivo (alpha-beta T cell depleted or CD34+ selected grafts) as acute GvHD prophylaxis
• The graft source is cord blood or bone marrow
• The donor or recipient has HLA DRB1*0301 or DRB1*1501 alleles
• The recipient has a very high disease risk index (DRI) based upon the data available at the time of eligibility assessment
• The recipient has a medical, behavioral, or social condition which in the opinion of the investigators would preclude compliance with the study

Related Conditions & MeSH terms

• Cytomegaloviral Infection
• Cytomegalovirus Infections
• Hematopoietic and Lymphoid System Neoplasm
• Infections

Intervention

Procedure:
• Allogeneic Hematopoietic Stem Cell Transplantation
Undergo standard of care allogeneic hematopoietic stem cell transplant
• Biospecimen Collection
Correlative studies

Biological:
• CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine
Given intradermally

Locations

Country	Name	City	State
United States	Roswell Park Cancer Institute	Buffalo	New York

Sponsors (1)

Lead Sponsor	Collaborator
Roswell Park Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of T cells	Includes CD4 T-cells, CD8 T-cells, delta gamma T-cells, and natural killer T-cells. Will be modeled as a function of time (treated as discrete) and random subject effect (through use of an auto-regressive covariance structure) with a linear mixed model. Mean differences of interest (i.e., changes after vaccination) will be evaluated by using Holm-Bonferroni adjusted tests on the appropriate contrasts of model estimates. All model assumptions will be evaluated graphically, and transformations will be applied as appropriate.	1 year
Other	T cell receptor diversity	Measured by Vbeta spectra-typing. Will be modeled as a function of time (treated as discrete) and random subject effect (through use of an auto-regressive covariance structure) with a linear mixed model. Mean differences of interest (i.e., changes after vaccination) will be evaluated by using Holm-Bonferroni adjusted tests on the appropriate contrasts of model estimates. All model assumptions will be evaluated graphically, and transformations will be applied as appropriate.	1 year
Other	Incidence of adverse events	Toxicities and adverse events (as per Common Terminology Criteria for Adverse Events version 5.0) will be summarized by attribution and grade using frequencies and relative frequencies.	Up to 2 years
Primary	Incidence of dose limiting toxicities	For each dose level of cytomegalovirus (CMV) pp65 peptide loaded alpha-type 1 polarized dendritic cell (CMV-alphaDC1) vaccination that is tested. Will be summarized by dose level using frequencies and relative frequencies.	Up to 2 years
Primary	Number of multifunctional CMV antigen specific T cells	The number of multifunctional CMV antigen specific T cells will be determined by flow cytometry before and after vaccination with CMV-alphaDC1. Assessed by the change in the number of CMV specific T cells before and after treatment, which is compared using a one-sided paired t-test. The number of CMV specific T cells will be summarized before and after treatment using the appropriate descriptive statistics, with the mean change estimated using a 90% confidence interval.	At days 28 (before vaccination), 42 (before vaccination), 56, 70, 84, 100, 180, 365
Primary	Number of CMV pp56 reactive T cells	The number of CMV pp65 reactive T cells will be determined by cytokine secretion (such as IFN-gamma) with ELISPOT before and after vaccination with CMV-alphaDC1. Assessed by the change in the number of CMV specific T cells before and after treatment, which is compared using a one-sided paired t-test. The number of CMV specific T cells will be summarized before and after treatment using the appropriate descriptive statistics, with the mean change estimated using a 90% confidence interval.	At days 28 (before vaccination), 42 (before vaccination), 56, 70, 84, 100, 180, 365
Secondary	Incidence of late CMV reactivation after allogeneic hematopoietic stem cell transplant	Will be summarized by dose level using the appropriate descriptive statistics; with estimates of rates obtained by 95% Jeffrey's prior confidence intervals.	From day 85 to 365
Secondary	Incidence of non-relapse mortality after allogeneic hematopoietic stem cell transplant	Will be summarized by dose level using the appropriate descriptive statistics; with estimates of rates obtained by 95% Jeffrey's prior confidence intervals.	Up to 2 years